EnBio Holdings, Inc. (6092) AI Stock Analysis

• Market Cap: ¥5.14B
• Dividend Yield: 1.43%
• Average Volume (3M): 26.57K
• Price to Earnings (P/E): 46.3
• Beta (1Y): 0.62
• Revenue Growth: 10.48%
• EPS Growth: -87.55%
• Country: JP
• Employees: 104
• Sector: Industrials
• Sector Strength: 72
• Industry: Specialty Business Services
• EPS (TTM): 1.12
• Shares Outstanding: 8,175,200
• 10 Day Avg. Volume: 22,480
• 30 Day Avg. Volume: 26,566
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥649.00
• Price Target Upside: 3.02% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: ¥649.00 ▲(3.02% Upside)

The overall stock score of 56 reflects the company's strong revenue growth and operational efficiency, offset by challenges in cash flow management and bearish technical indicators. The high P/E ratio suggests the stock may be overvalued, while the dividend yield offers moderate income potential.

EnBio Holdings, Inc. Business Overview & Revenue Model

Company Description

EnBio Holdings Co., Ltd. engages in soil and groundwater contamination, and renewable energy businesses in Japan. It imports and sells equipment, materials, and cleaning agents; and purchases, sells, and leases contaminated land. The company is also involved in solar power; biomass power generation; renewable energy power generation; water resource development; and ethical consumption promotion businesses. EnBio Holdings Co., Ltd. was incorporated in 1999 and is headquartered in Tokyo, Japan.

How the Company Makes Money

EnBio Holdings, Inc. generates revenue through the sale and implementation of its environmental biotechnology solutions. The company's primary revenue streams include fees from consulting services, sales of proprietary bioremediation products, and contracts for large-scale environmental projects. EnBio Holdings partners with government agencies, industrial clients, and private enterprises to provide tailored solutions that help meet regulatory requirements and sustainability goals. Additionally, the company may receive revenue from licensing agreements for its patented technologies and products.

EnBio Holdings, Inc. Financial Statement Overview

Summary

EnBio Holdings, Inc. shows strong revenue growth and operational efficiency with healthy EBIT and EBITDA margins. However, the decline in net income and challenges in cash flow management, particularly negative free cash flow, could pose risks.

Income Statement

EnBio Holdings, Inc. shows a robust performance with strong revenue growth of 11.44% from 2024 to 2025, indicating positive business momentum. The gross profit margin stands at 24.87% and the net profit margin at 4.24% for 2025, which are moderate but consistent over the years. However, the decline in net income from 2024 to 2025 suggests some pressure on profitability. The EBIT and EBITDA margins are healthy at 7.95% and 12.58%, respectively, reflecting efficient operational management.

Balance Sheet

The balance sheet of EnBio Holdings, Inc. reveals a solid equity base with a debt-to-equity ratio of 1.10, indicating a balanced capital structure. The return on equity (ROE) is relatively low at 4.95% for 2025, showing room for improvement in generating returns for shareholders. The equity ratio is 43.14%, suggesting a stable financial position with a reasonable level of leverage.

Cash Flow

The cash flow statement indicates challenges with free cash flow, which turned negative in 2025, driven by high capital expenditures. The operating cash flow to net income ratio is low at 0.05, highlighting potential inefficiencies in cash generation relative to net income. However, the company has maintained positive operating cash flow, which is a positive indicator of ongoing operational health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.67B	10.67B	9.58B	8.12B	8.99B	6.84B
Gross Profit	2.65B	2.65B	2.48B	2.76B	2.43B	1.89B
EBITDA	1.12B	1.34B	1.62B	1.76B	1.57B	981.00M
Net Income	452.69M	452.69M	708.76M	812.06M	654.05M	304.06M
Balance Sheet
Total Assets	21.20B	21.20B	19.31B	17.35B	16.37B	15.70B
Cash, Cash Equivalents and Short-Term Investments	3.29B	3.29B	3.60B	2.83B	2.37B	2.02B
Total Debt	10.10B	10.10B	8.62B	8.90B	8.58B	9.04B
Total Liabilities	11.96B	11.96B	10.72B	10.49B	10.40B	10.38B
Stockholders Equity	9.14B	9.14B	8.49B	6.79B	5.89B	5.29B
Cash Flow
Free Cash Flow	0.00	-1.44B	584.36M	824.13M	1.25B	-1.43B
Operating Cash Flow	0.00	21.92M	1.66B	1.99B	2.41B	297.16M
Investing Cash Flow	0.00	-1.60B	-1.58B	-1.77B	-1.48B	-2.16B
Financing Cash Flow	0.00	1.27B	638.92M	240.73M	-534.92M	928.54M

EnBio Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 630.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6092, the sentiment is Negative. The current price of 630 is below the 20-day moving average (MA) of 647.75, below the 50-day MA of 649.66, and above the 200-day MA of 606.70, indicating a neutral trend. The MACD of -5.06 indicates Positive momentum. The RSI at 38.45 is Neutral, neither overbought nor oversold. The STOCH value of 15.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6092.

EnBio Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7850	72 Outperform	¥2.59B	8.12	―	2.26%	2.78%	16.45%
7883	72 Outperform	¥5.44B	13.90	2.81%	2.28%	-1.10%	26.19%
7812	71 Outperform	¥5.78B	7.80	9.26%	4.06%	-1.48%	-19.07%
3948	66 Neutral	¥7.50B	41.25	1.73%	3.07%	-3.04%	-10.38%
7916	60 Neutral	¥4.78B	29.68	0.40%	3.20%	-0.55%	―
6092	56 Neutral	¥5.14B	46.28	―	1.43%	10.48%	-87.55%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%

EnBio Holdings, Inc. Corporate Events

EnBio Holdings Reports Fiscal Year 2025 Financial Results with Revenue Growth Amid Profit Decline

EnBio Holdings, Inc. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing an increase in net sales by 11.4% to ¥10,668 million. However, the company experienced a decline in ordinary profit and profit attributable to owners of the parent by 34.2% and 36.1%, respectively. The financial results reflect challenges in maintaining profitability despite revenue growth. The inclusion of two new companies, DEFNE ENERGY INVESTMENT INDUSTRY TRADE LIMITED and EnBio C West, G.K., in its consolidation scope indicates strategic expansion efforts. The forecast for the next fiscal year predicts further growth in net sales and profits, suggesting a positive outlook for the company’s future performance.